NeutriSci International Inc (NU) - Net Assets
Based on the latest financial reports, NeutriSci International Inc (NU) has net assets worth CA$-914.77K CAD (≈ $-661.73K USD) as of September 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$127.83K ≈ $92.47K USD) and total liabilities (CA$1.04 Million ≈ $754.20K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of NeutriSci International Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-914.77K |
| % of Total Assets | -715.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | -323.71% |
| 10-Year Change | -123.2% |
| Growth Volatility | 238.99 |
NeutriSci International Inc - Net Assets Trend (2001–2022)
This chart illustrates how NeutriSci International Inc's net assets have evolved over time, based on quarterly financial data. See NeutriSci International Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for NeutriSci International Inc (2001–2022)
The table below shows the annual net assets of NeutriSci International Inc from 2001 to 2022. For live valuation and market cap data, see NeutriSci International Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | CA$-616.97K ≈ $-446.31K |
-1196.16% |
| 2021-12-31 | CA$-47.60K ≈ $-34.43K |
+47.25% |
| 2020-12-31 | CA$-90.24K ≈ $-65.28K |
+42.24% |
| 2019-12-31 | CA$-156.24K ≈ $-113.02K |
-156.65% |
| 2018-12-31 | CA$275.79K ≈ $199.50K |
+109.91% |
| 2017-12-31 | CA$131.39K ≈ $95.04K |
-80.22% |
| 2016-12-31 | CA$664.22K ≈ $480.49K |
-8.63% |
| 2015-12-31 | CA$726.98K ≈ $525.89K |
-21.72% |
| 2014-12-31 | CA$928.71K ≈ $671.82K |
-65.08% |
| 2014-09-30 | CA$2.66 Million ≈ $1.92 Million |
+477.03% |
| 2012-12-31 | CA$-705.48K ≈ $-510.34K |
+92.26% |
| 2011-12-31 | CA$-9.12 Million ≈ $-6.60 Million |
-37.38% |
| 2010-12-31 | CA$-6.64 Million ≈ $-4.80 Million |
-46.35% |
| 2009-12-31 | CA$-4.53 Million ≈ $-3.28 Million |
-62.41% |
| 2008-12-31 | CA$-2.79 Million ≈ $-2.02 Million |
-222.10% |
| 2007-12-31 | CA$-866.86K ≈ $-627.07K |
-1368.13% |
| 2006-12-31 | CA$-59.05K ≈ $-42.71K |
+87.90% |
| 2005-12-31 | CA$-487.78K ≈ $-352.85K |
-94.86% |
| 2004-12-31 | CA$-250.32K ≈ $-181.08K |
-123.53% |
| 2003-12-31 | CA$1.06 Million ≈ $769.61K |
+674.90% |
| 2002-12-31 | CA$137.29K ≈ $99.32K |
-59.33% |
| 2001-12-31 | CA$337.55K ≈ $244.18K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NeutriSci International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3644718100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$31.03 Million | % |
| Other Comprehensive Income | CA$239.51K | % |
| Other Components | CA$4.58 Million | % |
| Total Equity | CA$-616.97K | 100.00% |
NeutriSci International Inc Competitors by Market Cap
The table below lists competitors of NeutriSci International Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intercede Group
LSE:IGP
|
$896.71K |
|
Urbanimmersive Inc
V:UI
|
$897.04K |
|
Lake Winn Resources Corp
V:LWR
|
$897.09K |
|
Pacific Imperial Mines Inc
V:PPM
|
$898.01K |
|
GenixPharmaceucticals Corporation
V:GENX
|
$885.77K |
|
Ristia Bintang Mahkotasejati
JK:RBMS
|
$883.63K |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
$882.96K |
|
Greencastle Resources Ltd.
V:VGN
|
$879.11K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeutriSci International Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -47,600 to -616,973, a change of -569,373.
- Net loss of 770,694 reduced equity.
- New share issuances of 196,774 increased equity.
- Other factors increased equity by 4,547.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-770.69K | -124.92% |
| Share Issuances | CA$196.77K | +31.89% |
| Other Changes | CA$4.55K | +0.74% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares NeutriSci International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CA$2.43 | CA$11.62 | x |
| 2002-12-31 | CA$1.98 | CA$11.62 | x |
| 2003-12-31 | CA$2.42 | CA$11.62 | x |
| 2004-12-31 | CA$-0.34 | CA$11.62 | x |
| 2005-12-31 | CA$-0.37 | CA$11.62 | x |
| 2006-12-31 | CA$-0.02 | CA$11.62 | x |
| 2007-12-31 | CA$-0.28 | CA$11.62 | x |
| 2008-12-31 | CA$-0.87 | CA$11.62 | x |
| 2009-12-31 | CA$-1.39 | CA$11.62 | x |
| 2010-12-31 | CA$-2.04 | CA$11.62 | x |
| 2011-12-31 | CA$-2.80 | CA$11.62 | x |
| 2012-12-31 | CA$-0.22 | CA$11.62 | x |
| 2015-12-31 | CA$0.02 | CA$11.62 | x |
| 2016-12-31 | CA$0.01 | CA$11.62 | x |
| 2017-12-31 | CA$0.00 | CA$11.62 | x |
| 2018-12-31 | CA$0.00 | CA$11.62 | x |
| 2019-12-31 | CA$0.00 | CA$11.62 | x |
| 2020-12-31 | CA$0.00 | CA$11.62 | x |
| 2021-12-31 | CA$0.00 | CA$11.62 | x |
| 2022-12-31 | CA$0.00 | CA$11.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeutriSci International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -168.37%
- • Asset Turnover: 1.38x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-169.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -4.54% | -342.03% | 0.01x | 1.02x | CA$-49.08K |
| 2002 | -145.86% | -8393.08% | 0.01x | 1.25x | CA$-213.99K |
| 2003 | -94.86% | -50638.03% | 0.00x | 1.23x | CA$-1.12 Million |
| 2004 | 0.00% | -2733.00% | 0.26x | 0.00x | CA$-2.75 Million |
| 2005 | 0.00% | -3198.82% | 0.17x | 0.00x | CA$-1.93 Million |
| 2006 | 0.00% | -463.34% | 0.73x | 0.00x | CA$-1.80 Million |
| 2007 | 0.00% | -482.56% | 2.98x | 0.00x | CA$-2.96 Million |
| 2008 | 0.00% | -662.43% | 1.70x | 0.00x | CA$-1.78 Million |
| 2009 | 0.00% | -360.16% | 2.90x | 0.00x | CA$-1.30 Million |
| 2010 | 0.00% | -982.07% | 2.39x | 0.00x | CA$-1.48 Million |
| 2011 | 0.00% | -907.23% | 2.15x | 0.00x | CA$-1.58 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | CA$7.98 Million |
| 2014 | -65.79% | -701.56% | 0.04x | 2.45x | CA$-2.02 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 2.76x | CA$-92.87K |
| 2015 | -550.97% | -14411.21% | 0.02x | 2.35x | CA$-4.08 Million |
| 2016 | -386.14% | -2046.12% | 0.11x | 1.72x | CA$-2.63 Million |
| 2017 | -1615.28% | -1404.81% | 0.25x | 4.58x | CA$-2.14 Million |
| 2018 | -864.02% | -2882.67% | 0.15x | 2.01x | CA$-2.41 Million |
| 2019 | 0.00% | -1670.71% | 0.19x | 0.00x | CA$-1.60 Million |
| 2020 | 0.00% | -2618.34% | 0.14x | 0.00x | CA$-1.94 Million |
| 2021 | 0.00% | -1943.53% | 0.10x | 0.00x | CA$-1.57 Million |
| 2022 | 0.00% | -168.37% | 1.38x | 0.00x | CA$-709.00K |
Industry Comparison
This section compares NeutriSci International Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $713,486,636
- Average return on equity (ROE) among peers: -56.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeutriSci International Inc (NU) | CA$-914.77K | -4.54% | N/A | $892.12K |
| Aurora Cannabis Inc (ACB) | $1.69 Million | -10.52% | 0.00x | $171.89 Million |
| Amotiv Limited (AOV) | $795.11 Million | 0.54% | 0.21x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-6.45 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $3.46 Million | -426.03% | 4.09x | $12.28 Million |
| Avant Brands Inc (AVNT) | $32.85 Million | -68.65% | 0.81x | $6.98 Million |
| Bausch Health Companies Inc (BHC) | $5.94 Billion | 40.44% | 5.31x | $1.87 Billion |
| CanadaBis Capital Inc (CANB) | $2.63 Million | 23.10% | 4.88x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $266.93 Million | -39.33% | 0.51x | $12.41 Million |
| Cipher Pharmaceuticals Inc (CPH) | $18.41 Million | -56.20% | 0.05x | $297.74 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $76.24 Million | -32.43% | 0.15x | $118.76 Million |
About NeutriSci International Inc
NeutriSci International Inc. develops and markets nutraceutical products in Canada, Germany, and Japan. It offers neuenergy, an energy tab designed to deliver enhanced focus and mental clarity. The company sells its products through a distribution network of retail storefront and online markets. NeutriSci International Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.